Cargando…

Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors

BACKGROUND: We have previously reported that the upregulation of galectin-9 (Gal-9) on CD4(+) and CD8(+) T cells in HIV patients was associated with impaired T cell effector functions. Gal-9 is a ligand for T cell immunoglobulin and mucin domain-3, and its expression on T cells in cancer has not bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okoye, Isobel, Xu, Lai, Motamedi, Melika, Parashar, Pallavi, Walker, John W, Elahi, Shokrollah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735134/ https://www.ncbi.nlm.nih.gov/pubmed/33310773 http://dx.doi.org/10.1136/jitc-2020-001849

Ejemplares similares

CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors
por: Bozorgmehr, Najmeh, et al.
Publicado: (2023)

1α,25(OH)(2)D(3) reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
por: Li, Peng, et al.
Publicado: (2022)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
por: Slattery, Karen, et al.
Publicado: (2021)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
por: Renken, Stefanie, et al.
Publicado: (2022)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
por: Patin, Emmanuel C, et al.
Publicado: (2022)

Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia
por: Bozorgmehr, Najmeh, et al.
Publicado: (2021)

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
por: Curti, Brendan D, et al.
Publicado: (2021)

Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells
por: Liu, Yue, et al.
Publicado: (2023)

Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3
por: Chung, Young Min, et al.
Publicado: (2021)

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
por: Judge, Sean J, et al.
Publicado: (2020)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
por: Dubois, Sigrid P, et al.
Publicado: (2021)

Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8(+) T cells against tumor
por: Shimizu, Kanako, et al.
Publicado: (2023)

SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA
por: Wu, Ruiyan, et al.
Publicado: (2020)

Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
por: Wang, Sheng, et al.
Publicado: (2023)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2021)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
por: Delahousse, Julia, et al.
Publicado: (2020)

p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
por: Lu, Chunwan, et al.
Publicado: (2020)

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
por: Dettling, Danielle E, et al.
Publicado: (2022)

Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
por: Darwich, Abbass, et al.
Publicado: (2021)

Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
por: Roche, Veronique, et al.
Publicado: (2023)

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
por: Rosen, David B, et al.
Publicado: (2022)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
por: Rischin, Danny, et al.
Publicado: (2021)

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
por: Bai, Xue, et al.
Publicado: (2021)

PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer
por: Newton, Hannah S, et al.
Publicado: (2020)

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
por: Rischin, Danny, et al.
Publicado: (2020)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
por: Guigay, Joël, et al.
Publicado: (2021)

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
por: Verschraegen, Claire F, et al.
Publicado: (2020)

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
por: Sharma, Sandhya, et al.
Publicado: (2023)

Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
por: Chakiryan, Nicholas H, et al.
Publicado: (2023)

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions
por: Maoz, Asaf, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7di1d61453384kphjod9jt14ru